Lilly’s Paying $1.1bn For Itch Advantage With Dermira’s Lebrikizumab

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Making a large acquisition heading into the JP Morgan Healthcare Conference for the second consecutive year, Lilly is buying Dermira and its Phase III atopic dermatitis drug lebrikizumab, setting up a competition with Sanofi’s Dupixent.

SC2001_M-A_730858819_1200.jpg
Lilly makes a big M&A deal around the JPM meeting for a second straight year

Not satisfied with the oral JAK inhibitor Olumiant (baricitinib) as its only potential competitor for Sanofi/Regeneron Pharmaceuticals Inc.’s atopic dermatitis blockbuster Dupixent (dupilumab), Eli Lilly & Co. agreed on 10 January to pay $1.1bn in cash for Dermira Inc. and its Phase III interleukin-13 inhibitor for that indication. Lilly expects to close its acquisition of the Menlo Park, CA-based dermatology drug developer by the end of the first quarter.

The acquisition of Dermira makes two years in a row that Lilly announced a large acquisition around the start of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.